Skandinaviska Enskilda Banken AB publ Acquires 53,100 Shares of Teva Pharmaceutical Industries Ltd. $TEVA

Skandinaviska Enskilda Banken AB publ raised its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 3.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 1,801,001 shares of the company’s stock after acquiring an additional 53,100 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Teva Pharmaceutical Industries were worth $36,380,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Advisors Asset Management Inc. bought a new position in shares of Teva Pharmaceutical Industries during the second quarter worth $41,000. Cromwell Holdings LLC lifted its stake in Teva Pharmaceutical Industries by 40.3% in the 3rd quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock worth $44,000 after purchasing an additional 629 shares in the last quarter. MAI Capital Management boosted its holdings in shares of Teva Pharmaceutical Industries by 26.8% during the 2nd quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after purchasing an additional 697 shares during the last quarter. LRI Investments LLC grew its position in shares of Teva Pharmaceutical Industries by 246.0% during the third quarter. LRI Investments LLC now owns 2,813 shares of the company’s stock valued at $57,000 after purchasing an additional 2,000 shares in the last quarter. Finally, JTC Employer Solutions Trustee Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the third quarter worth about $65,000. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $34.40 on Wednesday. The stock’s fifty day moving average is $32.31 and its 200 day moving average is $24.81. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $12.47 and a fifty-two week high of $37.35. The firm has a market capitalization of $39.46 billion, a PE ratio of 28.67, a PEG ratio of 1.94 and a beta of 0.70. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The business had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.36 billion. During the same quarter in the prior year, the firm posted $0.71 earnings per share. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analyst Ratings Changes

TEVA has been the subject of a number of research reports. Barclays increased their price target on Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research note on Friday, January 30th. Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. The Goldman Sachs Group raised their target price on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Wednesday, January 21st. Finally, Piper Sandler increased their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the company an “overweight” rating in a research report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $37.11.

Insider Activity

In related news, VP Richard Daniell sold 115,468 shares of the business’s stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total transaction of $3,311,622.24. Following the completion of the transaction, the vice president owned 48,384 shares in the company, valued at $1,387,653.12. The trade was a 70.47% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Amir Weiss sold 12,300 shares of the company’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the completion of the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at $170,630. This trade represents a 68.52% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 422,060 shares of company stock worth $12,254,965 in the last ninety days. 0.49% of the stock is currently owned by company insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.